A Series of Remote Melatonin Supplement Interventions for Poor Sleep: Protocol for a Feasibility Pilot Study for a Series of Personalized (N-of-1) Trials.

Autor:	Butler M; Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States., D'Angelo S; Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States., Perrin A; Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States., Rodillas J; Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States., Miller D; Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States., Arader L; Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.; St John's University, New York, NY, United States., Chandereng T; Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States., Cheung YK; Mailman School of Public Health, Columbia University, New York, NY, United States., Shechter A; Columbia University Irving Medical Center, New York, NY, United States., Davidson KW; Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.; Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Hempstead, NY, United States.
Jazyk:	angličtina
Zdroj:	JMIR research protocols [JMIR Res Protoc] 2023 Aug 03; Vol. 12, pp. e45313. Date of Electronic Publication: 2023 Aug 03.
DOI:	10.2196/45313
Abstrakt:	Background: Poor sleep, defined as short-duration or poor-quality sleep, is a frequently reported condition with many deleterious effects including poorer cognitive functioning, increased accidents, and poorer health. Melatonin has been shown to be an efficacious treatment to manage symptoms of poor sleep. However, the treatment effects of melatonin on sleep can vary greatly between participants. Personalized, or N-of-1, trial designs represent a method for identifying the best treatment for individual participants. Although using N-of-1 trials of melatonin to treat poor sleep is possible, the feasibility, acceptability, and effectiveness of N-of-1 trials using melatonin are unknown. Using the National Institutes of Health Stage Model for Behavioral Intervention Development, a stage IB (intervention refinement, modification, and adaptation and pilot testing) design appeared to be needed to address these feasibility questions. Objective: This trial series evaluates the feasibility, acceptability, and effectiveness of a series of personalized interventions for remote delivery of melatonin dose (3 and 0.5 mg) versus placebo supplements for self-reported poor sleep among 60 participants. The goal of this study is to provide valuable information about implementing remote N-of-1 randomized controlled trials to improve poor sleep. Methods: Participants will complete a 2-week baseline followed by six 2-week alternating intervention periods of 3 mg of melatonin, 0.5 mg of melatonin, and placebo. Participants will be randomly assigned to 2 intervention orders. The feasibility and acceptability of the personalized trial approach will be determined with participants' ratings of usability and satisfaction with the remote, personalized intervention delivery system. The effectiveness of the intervention will be measured using participants' self-reported sleep quality and duration and Fitbit tracker-measured sleep duration and efficiency. Additional measures will include ecological momentary assessment measures of fatigue, stress, pain, mood, concentration, and confidence as well as measures of participant adherence to the intervention, use of the Fitbit tracker, and survey data collection. Results: As of the submission of this protocol, recruitment for this National Institutes of Health stage IB personalized trial series is approximately 78.3% complete (47/60). We expect recruitment and data collection to be finalized by June 2023. Conclusions: Evaluating the feasibility, acceptability, and effectiveness of a series of personalized interventions of melatonin will address the longer term aim of this program of research-is integrating N-of-1 trials useful patient care? The personalized trial series results will be published in a peer-reviewed journal and will follow the CONSORT (Consolidated Standards of Reporting Trials) extension for N-of-1 trials (CENT 2015) reporting guidelines. This trial series was approved by the Northwell Health institutional review board. Trial Registration: ClinicalTrials.gov NCT05349188; https://www.clinicaltrials.gov/study/NCT05349188. International Registered Report Identifier (irrid): DERR1-10.2196/45313. (©Mark Butler, Stefani D’Angelo, Alexandra Perrin, Jordyn Rodillas, Danielle Miller, Lindsay Arader, Thevaa Chandereng, Ying Kuen Cheung, Ari Shechter, Karina W Davidson. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 03.08.2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu